<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Khalek IS</submitter><funding>DBT/Wellcome Trust India Alliance</funding><funding>Wellcome Trust</funding><pagination>eadk1867</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7617732</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(735)</volume><pubmed_abstract>Snakebite envenoming is a major global public health concern for which improved therapies are urgently needed. The antigenic diversity present in snake venom toxins from various species presents a considerable challenge to the development of a universal antivenom. Here, we used a synthetic human antibody library to find and develop an antibody that neutralizes long-chain three-finger α-neurotoxins produced by numerous medically relevant snakes. Our antibody bound diverse toxin variants with high affinity, blocked toxin binding to the nicotinic acetylcholine receptor in vitro, and protected mice from lethal venom challenge. Structural analysis of the antibody-toxin complex revealed a binding mode that mimics the receptor-toxin interaction. The overall workflow presented is generalizable for</pubmed_abstract><journal>Science translational medicine</journal><pubmed_title>Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins.</pubmed_title><pmcid>PMC7617732</pmcid><funding_grant_id>223619</funding_grant_id><funding_grant_id>221705/Z/20/Z</funding_grant_id><funding_grant_id>IA/I/19/2/504647</funding_grant_id><funding_grant_id>223619/Z/21/Z</funding_grant_id><pubmed_authors>Jardine JG</pubmed_authors><pubmed_authors>Casewell NR</pubmed_authors><pubmed_authors>Menzies SK</pubmed_authors><pubmed_authors>Sunagar K</pubmed_authors><pubmed_authors>Nguyen YTK</pubmed_authors><pubmed_authors>Saye-Francisco K</pubmed_authors><pubmed_authors>Burton DR</pubmed_authors><pubmed_authors>Kedzior M</pubmed_authors><pubmed_authors>Sok D</pubmed_authors><pubmed_authors>Limbo O</pubmed_authors><pubmed_authors>Stanfield RL</pubmed_authors><pubmed_authors>Misson Mindrebo L</pubmed_authors><pubmed_authors>Smith JM</pubmed_authors><pubmed_authors>Wilson IA</pubmed_authors><pubmed_authors>Verma M</pubmed_authors><pubmed_authors>Khochare S</pubmed_authors><pubmed_authors>Senji Laxme RR</pubmed_authors><pubmed_authors>Harrison RA</pubmed_authors><pubmed_authors>Khalek IS</pubmed_authors><pubmed_authors>Woehl J</pubmed_authors><pubmed_authors>Bore E</pubmed_authors><pubmed_authors>Tran Q</pubmed_authors><pubmed_authors>Kim Y</pubmed_authors><pubmed_authors>Patel RN</pubmed_authors><pubmed_authors>Ainsworth S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins.</name><description>Snakebite envenoming is a major global public health concern for which improved therapies are urgently needed. The antigenic diversity present in snake venom toxins from various species presents a considerable challenge to the development of a universal antivenom. Here, we used a synthetic human antibody library to find and develop an antibody that neutralizes long-chain three-finger α-neurotoxins produced by numerous medically relevant snakes. Our antibody bound diverse toxin variants with high affinity, blocked toxin binding to the nicotinic acetylcholine receptor in vitro, and protected mice from lethal venom challenge. Structural analysis of the antibody-toxin complex revealed a binding mode that mimics the receptor-toxin interaction. The overall workflow presented is generalizable for</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Feb</publication><modification>2026-04-08T19:14:01.12Z</modification><creation>2026-04-08T12:01:24.572Z</creation></dates><accession>S-EPMC7617732</accession><cross_references><pubmed>38381847</pubmed><doi>10.1126/scitranslmed.adk1867</doi></cross_references></HashMap>